{"id":"ribavirin-in-arm-1","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Hemolytic anemia"},{"rate":null,"effect":"Teratogenicity/embryocidal effects"},{"rate":"20-40","effect":"Fatigue"},{"rate":"20-30","effect":"Headache"},{"rate":"10-20","effect":"Dyspnea"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Insomnia"},{"rate":"10-20","effect":"Depression/mood changes"}]},"_chembl":{"chemblId":"CHEMBL1643","moleculeType":"Small molecule","molecularWeight":"244.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ribavirin is a guanosine analog that gets phosphorylated intracellularly and incorporated into viral RNA, causing chain termination and mutations. It also inhibits inosine monophosphate dehydrogenase (IMPDH), reducing guanosine nucleotide availability needed for viral replication. This dual mechanism makes it effective against a broad spectrum of RNA viruses.","oneSentence":"Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with the viral polymerase and depleting guanosine nucleotide pools.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:01.212Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C (in combination with interferon or direct-acting antivirals)"},{"name":"Severe respiratory syncytial virus (RSV) infection"},{"name":"Hemorrhagic fever with renal syndrome"},{"name":"Lassa fever"}]},"trialDetails":[{"nctId":"NCT06212336","phase":"PHASE2, PHASE3","title":"ISTH/ANRS 0409s INTEGRATE Lassa Fever Study","status":"RECRUITING","sponsor":"Irrua Specialist Teaching Hospital","startDate":"2025-05-02","conditions":"Lassa Fever","enrollment":1755},{"nctId":"NCT00630058","phase":"PHASE1","title":"A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-04","conditions":"Hepatitis C","enrollment":20},{"nctId":"NCT02940496","phase":"PHASE2","title":"Pembrolizumab (MK-3475) in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-12-09","conditions":"BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection","enrollment":15},{"nctId":"NCT06860334","phase":"PHASE2","title":"UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF","status":"NOT_YET_RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-07-01","conditions":"Crimean-Congo Hemorrhagic Fever","enrollment":378},{"nctId":"NCT01353911","phase":"PHASE2","title":"Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":368},{"nctId":"NCT02613403","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-10","conditions":"Hepatitis, Hepatitis C, Digestive System Diseases","enrollment":94},{"nctId":"NCT01058512","phase":"PHASE2","title":"A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy","status":"COMPLETED","sponsor":"Cellectar Biosciences, Inc.","startDate":"2010-03","conditions":"Hepatitis C","enrollment":22},{"nctId":"NCT05467826","phase":"PHASE4","title":"Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-09-01","conditions":"Hepatitis C, Cirrhosis","enrollment":100},{"nctId":"NCT04563208","phase":"PHASE2","title":"Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2020-12-09","conditions":"Covid19, SARS-CoV Infection","enrollment":80},{"nctId":"NCT02109744","phase":"PHASE1, PHASE2","title":"Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2014-03","conditions":"Acute Myelogenous Leukemia","enrollment":27},{"nctId":"NCT01380938","phase":"PHASE3","title":"Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)","status":"COMPLETED","sponsor":"Casa Sollievo della Sofferenza IRCCS","startDate":"2018-12-01","conditions":"Chronic Hepatitis","enrollment":1150},{"nctId":"NCT03512210","phase":"PHASE4","title":"Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2018-10-22","conditions":"Hepatitis C, HIV-1-infection, Liver Diseases","enrollment":400},{"nctId":"NCT03365635","phase":"PHASE4","title":"Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-09-22","conditions":"Hepatitis C, Hemodialysis, Nosocomial Infection","enrollment":6},{"nctId":"NCT00078403","phase":"PHASE2","title":"Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections, Hepatitis C, Liver Disease","enrollment":333},{"nctId":"NCT02455167","phase":"PHASE3","title":"Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2015-05","conditions":"Hepatitis C","enrollment":9},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT02723084","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-08","conditions":"Chronic Hepatitis C Virus, Hepatitis C Virus","enrollment":136},{"nctId":"NCT02243280","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-08","conditions":"Chronic Hepatitis C, Hepatitis C Virus, HCV","enrollment":174},{"nctId":"NCT01939197","phase":"PHASE2, PHASE3","title":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-08-30","conditions":"Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C","enrollment":318},{"nctId":"NCT02219503","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09","conditions":"Chronic Hepatitis C Infection, Compensated Cirrhosis","enrollment":60},{"nctId":"NCT01995071","phase":"PHASE2","title":"A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-11","conditions":"Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis","enrollment":89},{"nctId":"NCT02292719","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-12-19","conditions":"Chronic Hepatitis C Virus Infection","enrollment":70},{"nctId":"NCT00910624","phase":"PHASE3","title":"Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-06-22","conditions":"Hepatitis C, Chronic","enrollment":168},{"nctId":"NCT01425203","phase":"PHASE3","title":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-23","conditions":"Chronic Hepatitis C Genotype 1","enrollment":238},{"nctId":"NCT01932762","phase":"PHASE2","title":"Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-01","conditions":"Hepatitis C","enrollment":98},{"nctId":"NCT01080222","phase":"PHASE2","title":"A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2010-08","conditions":"Chronic Hepatitis C Virus Infection","enrollment":152},{"nctId":"NCT00237484","phase":"PHASE3","title":"Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07-18","conditions":"Hepatitis C, Chronic","enrollment":89},{"nctId":"NCT02175966","phase":"PHASE2","title":"Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-07-28","conditions":"Hepatitis C","enrollment":35},{"nctId":"NCT02601573","phase":"PHASE2","title":"Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-05","conditions":"Hepatitis C","enrollment":101},{"nctId":"NCT01598090","phase":"PHASE3","title":"Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-06-14","conditions":"Hepatitis C Virus","enrollment":881},{"nctId":"NCT03488485","phase":"NA","title":"Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2016-06-18","conditions":"Chronic Hepatitis c","enrollment":50000},{"nctId":"NCT02631772","phase":"PHASE4","title":"LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2016-06-01","conditions":"Hepatitis C","enrollment":32},{"nctId":"NCT02175758","phase":"PHASE2","title":"Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-07-07","conditions":"Hepatitis C Virus Infection","enrollment":106},{"nctId":"NCT01429792","phase":"PHASE4","title":"A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-09-25","conditions":"Hepatitis C, Chronic","enrollment":1013},{"nctId":"NCT01544920","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05-30","conditions":"Hepatitis C, Chronic","enrollment":737},{"nctId":"NCT01756079","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-02-06","conditions":"Hepatitis C","enrollment":58},{"nctId":"NCT01945294","phase":"PHASE3","title":"Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-10","conditions":"Hepatitis C, Chronic","enrollment":257},{"nctId":"NCT03105349","phase":"PHASE4","title":"A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A","status":"WITHDRAWN","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2017-07-01","conditions":"HCV","enrollment":""},{"nctId":"NCT01854697","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":"Chronic Hepatitis C Infection","enrollment":311},{"nctId":"NCT01911845","phase":"PHASE2","title":"An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-04","conditions":"Chronic Hepatitis C Infection, Chronic Hepatitis C","enrollment":38},{"nctId":"NCT03343444","phase":"PHASE3","title":"Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents","status":"UNKNOWN","sponsor":"Egyptian Liver Hospital","startDate":"2017-04-15","conditions":"Hepatitis C Virus Infection, Response to Therapy of","enrollment":80},{"nctId":"NCT02060058","phase":"PHASE3","title":"Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2013-11","conditions":"Hepatitis C, Chronic","enrollment":12},{"nctId":"NCT03186313","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection","status":"COMPLETED","sponsor":"Egyptian Liver Hospital","startDate":"2016-09","conditions":"Hepatitis C","enrollment":72},{"nctId":"NCT01782495","phase":"PHASE2","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-02-25","conditions":"Chronic Hepatitis C Infection","enrollment":129},{"nctId":"NCT01033448","phase":"PHASE4","title":"A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-12","conditions":"Hepatitis C, Chronic","enrollment":59},{"nctId":"NCT02446717","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04","conditions":"Chronic Hepatitis C, Hepatitis C Virus, HCV","enrollment":141},{"nctId":"NCT02265237","phase":"PHASE3","title":"A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10-28","conditions":"Hepatitis C Virus","enrollment":184},{"nctId":"NCT02959359","phase":"PHASE4","title":"DAA in the Risk of Recurrence After Curative Treatment of HCC","status":"WITHDRAWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2016-11","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT01962441","phase":"PHASE3","title":"SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-09-24","conditions":"Hepatitis C","enrollment":601},{"nctId":"NCT01805882","phase":"PHASE2","title":"Combination Therapy for Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-01","conditions":"Hepatitis C, Chronic","enrollment":229},{"nctId":"NCT01648140","phase":"PHASE2","title":"Dose Ranging of GSK2336805 in Combination Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-08-01","conditions":"Hepatitis C, Chronic","enrollment":286},{"nctId":"NCT02006745","phase":"PHASE3","title":"Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2014-01","conditions":"HIV","enrollment":20},{"nctId":"NCT00493805","phase":"PHASE4","title":"Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Hepatitis C, Chronic, Insulin Resistance","enrollment":59},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT00845065","phase":"PHASE3","title":"Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02","conditions":"Hepatitis C, Chronic","enrollment":202},{"nctId":"NCT00423670","phase":"PHASE2","title":"Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01","conditions":"Chronic Hepatitis C","enrollment":765},{"nctId":"NCT00277238","phase":"PHASE2","title":"CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-02","conditions":"Hepatitis, Chronic Active","enrollment":113},{"nctId":"NCT01446250","phase":"PHASE3","title":"Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1","status":"TERMINATED","sponsor":"Debiopharm International SA","startDate":"2011-12","conditions":"Hepatitis C","enrollment":8},{"nctId":"NCT02985281","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric Patients","status":"UNKNOWN","sponsor":"National Liver Institute, Egypt","startDate":"2016-12","conditions":"Pharmacological Action","enrollment":41},{"nctId":"NCT00759200","phase":"PHASE2","title":"Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Chronic Hepatitis C","enrollment":525},{"nctId":"NCT02165189","phase":"PHASE2","title":"An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2014-08","conditions":"Hepatitits C","enrollment":46},{"nctId":"NCT01278134","phase":"PHASE2","title":"A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-02","conditions":"Hepatitis C, Chronic","enrollment":170},{"nctId":"NCT01057667","phase":"PHASE2","title":"A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-02","conditions":"Hepatitis C, Chronic","enrollment":168},{"nctId":"NCT01318694","phase":"PHASE3","title":"Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2011-03","conditions":"Hepatitis C","enrollment":1081},{"nctId":"NCT01846832","phase":"PHASE3","title":"A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2013-09","conditions":"Hepatitis C, Chronic, Infection","enrollment":232},{"nctId":"NCT01482403","phase":"PHASE2","title":"A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11","conditions":"Hepatitis C, Chronic","enrollment":58},{"nctId":"NCT00192647","phase":"PHASE4","title":"A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-08","conditions":"Hepatitis C, Chronic","enrollment":896},{"nctId":"NCT02220868","phase":"PHASE4","title":"Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study","status":"COMPLETED","sponsor":"Saint Michael's Medical Center","startDate":"2014-07","conditions":"Hepatitis C Infection, HIV Infection","enrollment":10},{"nctId":"NCT01500772","phase":"PHASE3","title":"Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C","status":"TERMINATED","sponsor":"Debiopharm International SA","startDate":"2012-03","conditions":"Hepatitis C","enrollment":6},{"nctId":"NCT01701063","phase":"PHASE1, PHASE2","title":"An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-01","conditions":"Hepatitis C","enrollment":42},{"nctId":"NCT01458535","phase":"PHASE2","title":"A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-09","conditions":"Hepatitis C Virus","enrollment":61},{"nctId":"NCT02216422","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09","conditions":"Chronic Hepatitis C Virus (HCV) Infection","enrollment":36},{"nctId":"NCT01296451","phase":"PHASE1","title":"Study of a New MVA Vaccine for Hepatitis C Virus","status":"COMPLETED","sponsor":"ReiThera Srl","startDate":"2010-12","conditions":"Hepatitis C Infection","enrollment":55},{"nctId":"NCT01970904","phase":"NA","title":"Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2013-10","conditions":"Hepatitis C, Liver Disease","enrollment":147},{"nctId":"NCT02098616","phase":"NA","title":"Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus","status":"COMPLETED","sponsor":"Timothy Morgan, MD","startDate":"2014-07","conditions":"Hepatitis C","enrollment":25},{"nctId":"NCT01912495","phase":"PHASE2","title":"Dutch Acute HCV in HIV Study (DAHHS)","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2013-08","conditions":"Hepatitis C, Human Immunodeficiency Virus","enrollment":65},{"nctId":"NCT00537407","phase":"PHASE2","title":"A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2007-09","conditions":"Chronic Hepatitis C","enrollment":50},{"nctId":"NCT01728324","phase":"PHASE3","title":"Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-11","conditions":"Hepatitis C, Chronic","enrollment":496},{"nctId":"NCT01724086","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-10","conditions":"Chronic Hepatitis C","enrollment":90},{"nctId":"NCT01425970","phase":"PHASE2","title":"Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C","enrollment":210},{"nctId":"NCT00160251","phase":"PHASE2","title":"Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":"Chronic Hepatitis C","enrollment":357},{"nctId":"NCT01170962","phase":"PHASE2","title":"Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-08","conditions":"Hepatitis C Virus","enrollment":512},{"nctId":"NCT01389323","phase":"PHASE3","title":"BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-09","conditions":"Hepatitis C","enrollment":448},{"nctId":"NCT01016912","phase":"PHASE2","title":"Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Hepatitis C Infection","enrollment":51},{"nctId":"NCT01193361","phase":"PHASE2","title":"Ph IIA Study (SOC +/- NS5B)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-10","conditions":"Hepatitis C Virus","enrollment":39},{"nctId":"NCT01616524","phase":"PHASE3","title":"Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-07","conditions":"Hepatitis C Virus (HCV)","enrollment":880},{"nctId":"NCT01718145","phase":"PHASE3","title":"A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-11","conditions":"Hepatitis C Virus Infection","enrollment":258},{"nctId":"NCT01030432","phase":"PHASE2","title":"Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-02","conditions":"Hepatitis C Virus","enrollment":285},{"nctId":"NCT01581203","phase":"PHASE3","title":"Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C Virus","enrollment":748},{"nctId":"NCT01012895","phase":"PHASE2","title":"Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Chronic Hepatitis C","enrollment":215},{"nctId":"NCT01017575","phase":"PHASE2","title":"Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Hepatitis C Infection","enrollment":55},{"nctId":"NCT00984620","phase":"PHASE2","title":"Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-09","conditions":"Hepatitis C","enrollment":160},{"nctId":"NCT01442311","phase":"NA","title":"Directly Observed Hepatitis C Treatment in Methadone Clinics","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2007-10","conditions":"Hepatitis C, Medication Adherence","enrollment":80},{"nctId":"NCT01094873","phase":"PHASE1","title":"Study of a Novel Therapeutic Vaccine for Hepatitis C Virus","status":"COMPLETED","sponsor":"ReiThera Srl","startDate":"2009-11","conditions":"Hepatitis C","enrollment":35},{"nctId":"NCT01852604","phase":"PHASE2","title":"Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-03","conditions":"Chronic Hepatitis C Virus","enrollment":143},{"nctId":"NCT01466790","phase":"PHASE2","title":"A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-01","conditions":"Hepatitis C","enrollment":168},{"nctId":"NCT00724295","phase":"","title":"Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-04","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":1077},{"nctId":"NCT00724230","phase":"","title":"Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-02","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":505},{"nctId":"NCT01691235","phase":"","title":"SIMpill Medication Dispensing Device in the Treatment of HCV","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2012-09","conditions":"Chronic Hepatitis C Virus","enrollment":""},{"nctId":"NCT01441180","phase":"PHASE1, PHASE2","title":"GS-7977 With Ribavirin for Hepatitis C (SPARE)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09","conditions":"Hepatitis C","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ribavirin in Arm 1","genericName":"Ribavirin in Arm 1","companyName":"MinaPharm Pharmaceuticals","companyId":"minapharm-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with the viral polymerase and depleting guanosine nucleotide pools. Used for Chronic hepatitis C (in combination with interferon or direct-acting antivirals), Severe respiratory syncytial virus (RSV) infection, Hemorrhagic fever with renal syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}